Cardiol Therapeutics (CRDL) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Zura Bio (ZURA) over the past year, losing 11.3% versus a loss of 74.4%. Cardiol Therapeutics is the larger company by market cap ($110.1 million vs $89.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | ZURA |
|---|---|---|
| Share price | $0.8626 | $0.9305 |
| Market cap | $110.14M | $89.63M |
| 1-day change | -2.28% | -2.30% |
| YTD return | -9.58% | -82.24% |
| 1-year return | -11.35% | -74.37% |
| 5-year return | -60.06% | — |
| EPS (TTM) | $-0.24 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-68.65M |
| 52-week high | $2.34 | $7.44 |
| 52-week low | $0.8417 | $0.919 |
| Distance from 52-week high | -63.14% | -87.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +874.96% | +759.75% |
| Average volume | 1.20M | 4.47M |
| Shares outstanding | 127.69M | 96.33M |
| Employees | 18 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed ZURA by 63.0 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
CRDL vs ZURA FAQ
Which is bigger, Cardiol Therapeutics or Zura Bio?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $110.14M compared with $89.63M for Zura Bio (ZURA).
Which stock has performed better over the past year, CRDL or ZURA?
CRDL returned -11.35% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.